Clene MS Treatment Presented at 2024 American Academy of Neurology

 

• Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)
• Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)
• Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observed
• First Phase 2 clinical MS trial of a non-immunomodulatory drug to meet a clinical outcome of improved function supporting remyelination and reparative effects

https://www.globenewswire.com/news-release/2024/04/16/2864082/0/en/Evidence-for-Clene-s-CNM-Au8-as-a-Treatment-for-Repair-and-Remyelination-in-Multiple-Sclerosis-Presented-in-the-Emerging-Science-Session-at-the-2024-American-Academy-of-Neurology-A.html